Crataegi flores (Herbal raw material) Instructions for Use
ATC Code
C01EB04 (Hawthorn glycosides)
Active Substance
Crataegi folium cum flore (DAB German Pharmacopoeia)
Clinical-Pharmacological Group
Herbal preparation used for functional disorders of the cardiovascular system
Pharmacotherapeutic Group
Cardiotonic agent of plant origin
Pharmacological Action
A herbal remedy. It has an antiarrhythmic and hypotensive effect, improves coronary and cerebral circulation, and reduces heart rate.
It lowers the excitability of the central nervous system, reduces the cholesterol content in the blood and increases the amount of lecithin; it normalizes blood clotting parameters.
In cases of hypogalactia, it increases lactation and eliminates dyspeptic phenomena in infants.
The hypotensive effect is more pronounced than that of hawthorn fruit.
Indications
Tachycardia, arterial hypertension, chronic heart failure (stages I-IIa), atherosclerosis, angina pectoris (including vasospastic angina), neurocirculatory dystonia, astheno-neurotic conditions, post-infarction cardiosclerosis, atrial tachyarrhythmia, paroxysmal supraventricular tachycardia, extrasystole, digitalis intoxication.
Insomnia, thyrotoxicosis; pneumonia, acute respiratory viral infections, cardialgia, climacteric syndrome (as part of combination therapy).
ICD codes
| ICD-10 code | Indication |
| E05 | Thyrotoxicosis [hyperthyroidism] |
| F45.3 | Somatoform dysfunction of the autonomic nervous system |
| F48.0 | Neurasthenia |
| F51.0 | Nonorganic insomnia |
| I10 | Essential [primary] hypertension |
| I20 | Angina pectoris |
| I25.8 | Other forms of chronic ischemic heart disease |
| I47.1 | Supraventricular tachycardia |
| I48 | Atrial fibrillation and flutter |
| I49.4 | Other and unspecified premature depolarization |
| I50.0 | Congestive heart failure |
| I70 | Atherosclerosis |
| J06.9 | Acute upper respiratory infection, unspecified |
| J15 | Bacterial pneumonia, not elsewhere classified |
| N95.1 | Menopausal and other perimenopausal disorders |
| N95.3 | States associated with artificial menopause |
| R00.0 | Tachycardia, unspecified (including nodal (sinus) NOS) |
| R07.2 | Pain in the heart region |
| T46.0 | Poisoning by cardiac glycosides and drugs of similar action |
| ICD-11 code | Indication |
| 5A02.Z | Thyrotoxicosis, unspecified |
| 6A8Z | Affective disorders, unspecified |
| 6C20.Z | Bodily distress disorder, unspecified |
| 7A00 | Chronic insomnia |
| 7A01 | Acute insomnia |
| 7A0Z | Insomnia disorders, unspecified |
| BA00.Z | Essential hypertension, unspecified |
| BA40.Z | Angina pectoris, unspecified |
| BA5Z | Chronic ischemic heart disease, unspecified |
| BC81.0 | Ectopic atrial tachycardia |
| BC81.1 | Nodal ectopic tachycardia |
| BC81.20 | CTI [cavotricuspid isthmus]-dependent atrial tachycardia by "macro re-entry" mechanism |
| BC81.21 | Atrial tachycardia by "macro re-entry" mechanism not associated with scar or cavotricuspid isthmus |
| BC81.2Z | Atrial tachycardia by "macro re-entry" mechanism, unspecified |
| BC81.5 | Sinoatrial reentrant tachycardia |
| BC81.7Z | Atrioventricular reentrant tachycardia, unspecified |
| BC81.8 | Atrioventricular nodal reentrant tachycardia |
| BC81.Z | Supraventricular tachyarrhythmia, unspecified |
| BD10 | Congestive heart failure |
| BD40.Z | Atherosclerosis of peripheral arteries, unspecified |
| BE2Y | Other specified diseases of the circulatory system |
| CA07.0 | Acute upper respiratory tract infection of unspecified site |
| CA40.0Z | Bacterial pneumonia, unspecified |
| GA30.00 | Menopausal or climacteric states in women |
| GA30.3 | States associated with artificial menopause |
| MC81.Z | Abnormalities of heart rhythm, unspecified |
| MC86 | Precordial pain |
| NE60 | Poisoning by drugs, medicaments or biological substances, not elsewhere classified |
Dosage Regimen
| The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen. |
Prepare as an infusion (tea). Place 1-2 grams (approximately 1 tablespoon) of crushed herbal raw material into an enamel or glass vessel.
Pour 200 ml (one cup) of hot boiled water over the raw material. Close the lid and heat in a boiling water bath for 15 minutes.
Cool the infusion at room temperature for 45 minutes. Strain the resulting liquid, then squeeze out the remaining plant material.
Bring the volume of the finished infusion to 200 ml with boiled water. Take the prepared infusion orally, 2-3 times per day.
Take 1/2 to 1/3 cup ( 100-150 ml) per dose. Take 30-40 minutes before meals.
The duration of treatment is determined by the physician based on the disease severity and achieved therapeutic effect.
For functional cardiovascular disorders, the typical treatment course is 3-4 weeks. For chronic heart failure, long-term use may be required.
Do not use the prepared infusion if it becomes cloudy or shows signs of spoilage. Prepare a fresh infusion daily; do not store for more than 24 hours in a cool place.
Adverse Reactions
Possibleallergic reactions; bradycardia (with prolonged use); nausea, vomiting, intestinal colic (when taken on an empty stomach).
Contraindications
Hypersensitivity to the plant.
Use in Pregnancy and Lactation
The possibility of use depends on the specific drug used containing hawthorn flowers and leaves.
Storage Conditions
Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.
Dispensing Status
Over-the-Counter
Important Safety Information
This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.
Medical DisclaimerBrand (or Active Substance), Marketing Authorisation Holder, Dosage Form
Herbal raw material: bags 50 g.
Marketing Authorization Holder
Microgen NPO, JSC (Russia)
Dosage Form
| Crataegi flores | Herbal raw material: bags 50 g. |
Dosage Form, Packaging, and Composition
| Herbal raw material | 1 bag |
| Common hawthorn flowers | 50 g |
50 g – Paper bags.
Herbal raw material - powder 2 g: filter-bags 10 pcs.
Marketing Authorization Holder
Microgen NPO, JSC (Russia)
Dosage Form
| Crataegi flores | Herbal raw material – powder 2 g: filter-bags 10 pcs. |
Dosage Form, Packaging, and Composition
| Herbal raw material – powder | 1 filter-bag |
| Common hawthorn flowers | 2 g |
2 g – filter-bags (10) – cardboard packs.
Herbal raw material - powder 2 g: filter bags 10 or 20 pcs.
Marketing Authorization Holder
Fito-Em Agrarian And Industrial Firm, CJS (Russia)
Dosage Form
| Crataegi flores | Herbal raw material – powder 2 g: filter bags 10 or 20 pcs. |
Dosage Form, Packaging, and Composition
| Herbal raw material – powder | 1 filter-bag |
| Common hawthorn flowers | 2 g |
2 g – filter-bags (10) – cardboard packs.
2 g – filter-bags (20) – cardboard packs.
